BiotechTube

prednisone

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Giant Cell Arteritis

Conditions

Giant Cell Arteritis

Trial Timeline

Sep 20, 2018 → Nov 25, 2020

NCT ID
NCT03827018

About prednisone

prednisone is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03827018. Target conditions include Giant Cell Arteritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03827018Phase 2Completed

Competing Products

20 competing products in Giant Cell Arteritis

See all competitors
ProductCompanyStageHype Score
PexidartinibDaiichi SankyoPhase 2
52
PexidartinibDaiichi SankyoPhase 3
77
PexidartinibDaiichi SankyoApproved
85
BaricitinibEli LillyPhase 2
52
Upadacitinib + Corticosteroid (CS)AbbViePhase 3
77
dovitinibNovartisPhase 2
52
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3
77
Secukinumab 300 mg, s.c. + Prednisolone + PlaceboNovartisPhase 2
52
SecukinumabNovartisPhase 1
33
Secukinumab 300 mg + Secukinumab 150 mgNovartisPhase 3
77
Tocilizumab + PlaceboRochePhase 3
77
Tocilizumab + PrednisoneRocheApproved
85
TocilizumabRochePhase 3
77
TocilizumabRochePhase 1
33
ValganciclovirRocheApproved
85
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + MethotrexateRochePhase 3
77
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)RochePhase 2
52
tocilizumab and IV steroids combinationRochePhase 2
52
DenosumabAmgenApproved
84
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]AmgenPhase 2
51

Other Products from Kiniksa Pharmaceuticals

Rilonacept + PlaceboPhase 3
72
KPL-387 + PlaceboPhase 2/3
60
mavrilimumabPhase 2/3
60
Mavrilimumab + PlacebosPhase 2
47
Mavrilimumab + PlacebosPhase 2
47